| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9283211 | Microbes and Infection | 2005 | 5 Pages |
Abstract
Modified vaccinia virus Ankara (MVA) is a potent vaccine vector, which proved its safety, immunogenity and efficacy in preclinical and clinical studies. The rational for the development of a vaccine against HIV based on the regulatory protein Nef delivered by MVA combined with a V2-deleted Env protein is discussed.
Keywords
HIV envcGMPHAARTICSHIV NefIFNγSIVHuman leucocyte antigensHLAModified vaccinia virus Ankarainterferon-gammacurrent Good Manufacturing PracticesHighly active anti-retroviral therapyintracellular cytokine stainingSHIVMVAhuman immunodeficiency virusHIVsimian-human immunodeficiency virusSimian immunodeficiency virus
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Volker Erfle, Frank D. Goebel, Carlos A. Guzman, Roger Le Grand,